Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Will Stocks Gain After The Elections? & Earnings From CVS, LLY, HEAR

Published 11/06/2018, 01:44 AM
Updated 07/09/2023, 06:31 AM
LLY
-
AET
-
CVS
-
META
-
HEAR
-
REGN
-

On today’s episode of Free Lunch, Ryan McQueeney chats with Dave Bartosiak about the near-term outlook for stocks after the midterm elections and the earnings outlook for Turtle Beach ahead of its report. The host also recaps earnings results from CVS, Eli Lilly, and Regeneron.

Want more video content from Zacks? Subscribe to Zacks Investment News now!

Free Lunch is presented by Zacks Investment Research. It is streamed live, four times per week, and features breaking news and analysis from Zacks strategists. Free Lunch is available on YouTube, Facebook (NASDAQ:FB) Live, Twitter, Ustream, and more.

U.S. stocks moved modestly higher in morning trading Tuesday, the same day millions of citizens are heading to the polls to cast votes in the midterm elections.

Wall Street appears to be handicapping a Democratic shift in the House of Representatives, as most opinion polls are calling for the party to take control of the chamber. Those same polls are also predicting that the Republicans will retain their lead in the Senate, meaning we could soon have a split Congress.

Interestingly enough, stocks have historically performed better during periods of Congressional gridlock, and if anything, investors will be happy to move past the uncertainty of the elections themselves. Plus, many of the same fundamental tailwinds and headwinds affecting equity prices will remain, regardless of the federal government’s s partisan makeup.

And as the votes roll in, so too are the Q3 earnings reports. This morning was a busy session for pre-market reports in the broader medical space, with the likes of CVS (NYSE:CVS) , Eli Lilly (NYSE:LLY) , and Regeneron (NASDAQ:REGN) filing before the bell.

Results from these companies were relatively positive, although mixed in some areas. CVS topped estimates on both lines and said its merger with Aetna (NYSE:AET) would be complete by Thanksgiving, Eli Lilly surpassed EPS projections, and Regeneron crushed profit expectations but missed revenue estimates.

Ryan covers all of these reports and gives his perspective on how Wall Street is feeling about the midterms on today’s show!

Later, he checks in with Dave Bartosiak to continue chatting about the near-term outlook for stocks after the midterms. Dave starts by showing an interesting technical trend that has developed in the Nasdaq QQQ, where bulls and bears have battled to keep the stock above and below certain moving averages and indicators.

Dave also suggests that part of this battle has to do with the event risk of the midterms, so he explains how and why Wall Street prices in risk when facing these uncertainties.

Finally, Dave highlights Turtle Beach (NASDAQ:HEAR) , which is scheduled to announce its latest quarterly results after the bell. He touches on the sentiment surrounding the stock and recommends a specific options play for those who are optimistic about the gaming headset maker. Make sure to check out the show to hear more!

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>



Eli Lilly and Company (LLY): Free Stock Analysis Report

Turtle Beach Corporation (HEAR): Free Stock Analysis Report

NASDAQ-100 SHRS (QQQ): ETF Research Reports

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

CVS Health Corporation (CVS): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.